---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-24-000162"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:30:01.813275+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q2 revenue $8.4B (+5.3%); raises FY25 organic growth and EPS guidance

## Summary
- GAAP diluted EPS $0.99 (up 46% YoY); non-GAAP diluted EPS $1.26 (up 1% as reported, 8% constant currency).
- Revenue $8.403B, organic growth 5.0%; driven by TAVR, PFA, leadless pacemakers, Diabetes, Spine, Neuromodulation.
- FY25 organic revenue growth guidance raised to 4.75%-5% from 4.5%-5%; non-GAAP EPS guidance raised to $5.44-$5.50 from $5.42-$5.50.
- Diabetes revenue $686M (+12.4% as reported, +11% organic) on continued adoption of MiniMed 780G AID system.
- Cardiovascular portfolio revenue $3.102B (+6.1% as reported, +5.6% organic) with high-single digit growth in Structural Heart (Evolut FX+ TAVR launch).

## SEC filing metadata
- accession: 0001613103-24-000162
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310324000162/0001613103-24-000162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310324000162/mdt-20241119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-24-000162
- JSON: https://secwatch.observer/filing/0001613103-24-000162.json
- Plain text: https://secwatch.observer/filing/0001613103-24-000162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.